Adaptimmune Therapeutics plc - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ADAP Nasdaq 2830 www.adaptimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adaptimmune Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - Jun 30th, 2025 9:14 am
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week - Jun 27th, 2025 9:01 am
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - Jun 26th, 2025 9:00 am
General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls - Jun 26th, 2025 7:49 am
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading - Jun 25th, 2025 9:04 am
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading - Jun 23rd, 2025 9:14 am
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - Jun 17th, 2025 9:03 am
Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ... - May 14th, 2025 1:05 am
Adaptimmune Reports Q1 Financial Results and Provides Business Update - May 13th, 2025 5:30 am
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 - May 7th, 2025 10:00 am
ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story - Mar 25th, 2025 3:26 am
Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ... - Mar 21st, 2025 1:01 am
ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options - Mar 20th, 2025 6:05 am
Adaptimmune Provides Q4 and Full Year 2024 Business Update - Mar 20th, 2025 5:00 am
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Mar 18th, 2025 5:00 am
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025 - Mar 12th, 2025 2:54 pm
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge funds - Mar 4th, 2025 3:39 am
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Jan 30th, 2025 2:00 pm
Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years ago - Jan 22nd, 2025 5:20 am
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) - Jan 13th, 2025 6:00 am